Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Pini Tsukerman"'
3
Abstract 6657: Phase I trial of first-in-class anti-PVR mAb NTX1088: Restoration of DNAM1 expression as MOA for enhanced antitumor immunity
Autor: Anas Atieh, Akram Obiedat, Alon Vitenshtein, Guy Cinamon, Keren Paz, Tihana lenac, Paola Kucan, Marija Mazor, Ofer Mandelboim, Stipan Jonji, Pini Tsukerman
Publikováno v: Cancer Research. 83:6657-6657
NTX1088, a first-in-class anti-PVR (CD155) monoclonal antibody (mAb), is currently evaluated in a Phase 1, open-label, multi-center study (NCT05378425), initiated at MD Anderson Cancer center. Study objectives are safety, dose-finding, and efficacy w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb26b327a488a13cee12264095cc4032
https://doi.org/10.1158/1538-7445.am2023-6657
Zobrazit plný text záznamu
4
Abstract 5534: NTX-1088, a first-in-class anti-PVR mAb mediates DNAM1-dependent antitumor immunity
Autor: Akram Obiedat, Anas Atieh, Guy Cinamon, Keren Paz, Paola Kucan Brilc, Lea Hirsl, Tihana Lenac Roviš, Ofer Mandelboim, Stipan Jonjic, Pini Tsukerman
Publikováno v: Cancer Research. 82:5534-5534
Poliovirus receptor (PVR, CD155), expressed on the surface of cancer cells, represents a resistance mechanism to approved immune checkpoint inhibitors (ICIs). It is a key regulator of immune activation, that modifies function through multiple mechani
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e191c8ab4710f528efffbbedcb0fe40b
https://doi.org/10.1158/1538-7445.am2022-5534
Zobrazit plný text záznamu
5
Abstract P075: NTX-1088, a potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity
Autor: Pini Tsukerman, Anas Atieh, Akram Obeidat, Keren Paz, Guy Cinamon, Tihana Lenac Rovis, Paola Kucan Brlic, Lea Hirsl, Stipan Jonjić, Ofer Mandelboim
Publikováno v: Cancer Immunology Research. 10:P075-P075
The poliovirus receptor (PVR, CD155) represents a resistance mechanism to approved immune checkpoint inhibitors (ICIs). It is a key regulator of immune activation, that modifies immune function through multiple mechanisms. Increased levels of PVR exp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bbf732cdd4d08e917f2aedf27d976ed0
https://doi.org/10.1158/2326-6074.tumimm21-p075
Zobrazit plný text záznamu
6
Targeting PVR (CD155) and its receptors in anti-tumor therapy
Autor: Paola Kucan Brlic, Stipan Jonjić, Guy Cinamon, Ofer Mandelboim, Tihana Lenac Rovis, Pini Tsukerman
Publikováno v: Cellular and Molecular Immunology
Volume 16
Issue 1
Poliovirus receptor (PVR, CD155) has recently been gaining scientific interest as a therapeutic target in the field of tumor immunology due to its prominent endogenous and immune functions. In contrast to healthy tissues, PVR is expressed at high lev
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::793df098d31b5a4e4af9601be438fdfd
https://doi.org/10.1038/s41423-018-0168-y
Zobrazit plný text záznamu
7
Abstract P102: NTX-1088, A potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity
Autor: Pini Tsukerman, Anas Atieh, Akram Obeidat, Keren Paz, Guy Cinamon, Tihana Lenac Roviš, Lea Hirsl, Paola Kucan Brilc, Stipan Jonjic, Ofer Mandelboim
Publikováno v: Molecular Cancer Therapeutics. 20:P102-P102
The poliovirus receptor (PVR, CD155) represents a resistance mechanism to approved immune checkpoint inhibitors (ICIs). It is a key regulator of immune activation, that modifies immune function through multiple mechanisms. Increased levels of PVR exp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66cf0c3b623d55dcecc694bc5edb8f6d
https://doi.org/10.1158/1535-7163.targ-21-p102
Zobrazit plný text záznamu
8
254 NTX-1088, a potent anti-PVR Mab induces DNAM1-mediated antitumor immunity
Autor: Anas Atieh, Lea Hiršl, Keren Paz, Tihana Lenac Rovis, Stipan Jonjić, Guy Cinamon, Pini Tsukerman, Paola Kucan Brlic, Ofer Mandelboim, Akram Obiedat
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPoliovirus receptor (PVR, CD155) represents a resistance mechanism to approved immune checkpoint inhibitors (ICIs). It is a key regulator of immune activation, that modifies function through multiple mechanisms. Increased PVR expression lev
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cff487abe0424b183169157ad2d85538
https://doi.org/10.1136/jitc-2021-sitc2021.254
Zobrazit plný text záznamu
9
PILRα binds an unknown receptor expressed primarily on CD56bright and decidual-NK cells and activates NK cell functions
Autor: Pini Tsukerman, Rachel Yamin, Yoav Bauman, Ofer Mandelboim, Yael Ophir, Moriya Gamliel, Alexandra Duev-Cohen
Publikováno v: Oncotarget
// Yael Ophir 1 , Alexandra Duev-Cohen 1 , Rachel Yamin 1 , Pini Tsukerman 1 , Yoav Bauman 1 , Moriya Gamliel 1 and Ofer Mandelboim 1 1 The Lautenberg Center for General and Tumor Immunology, The BioMedical Research Institute Israel-Canada of The Fac
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1f5aaba185e818bc2abfb27955ee19d
http://europepmc.org/articles/PMC5173034
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje